Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutetium Lu 177 Dotatate in Metastatic Prostate Cancer With Neuroendocrine Differentiation
NCT05691465Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2023
- Primary completion
- Jun 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium Lu 177 dotatate in prostate cancer (PCa), sponsored by National Cancer Institute. Started Dec 2023; status: recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05691465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05691465.